Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets
Neurocrine Biosciences Deferred Tax Assets and Other Non-Current Assets increased by 23.7% to $73.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 381.0%, from $15.30M to $73.60M. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets and Other Non-Current Assets shows an upward trend with a 56.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryLiquidity
SignalContext dependent
VolatilityStable
First reportedQ4 2019
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase generally reflects a growing long-term asset base or deferred tax position, while a decrease suggests asset liquidation or tax benefit utilization.
Detailed definition
This is the aggregate balance of non-current deferred tax assets and other miscellaneous non-current assets not classifi...
Peer comparison
Commonly found in the non-current asset section of balance sheets for large, diversified financial firms.
Metric ID:
deferred_tax_assets_other_noncurrentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.20M | $3.20M | $4.40M | $10.10M | $10.00M | $10.50M | $25.00M | $24.90M | $35.90M | $43.10M | $49.60M | $50.90M | $57.80M | $61.60M | $52.00M | $15.30M | $21.60M | $20.30M | $59.50M | $73.60M |
| QoQ Change | — | +0.0% | +37.5% | +129.5% | -1.0% | +5.0% | +138.1% | -0.4% | +44.2% | +20.1% | +15.1% | +2.6% | +13.6% | +6.6% | -15.6% | -70.6% | +41.2% | -6.0% | +193.1% | +23.7% |
| YoY Change | — | — | — | — | +212.5% | +228.1% | +468.2% | +146.5% | +259.0% | +310.5% | +98.4% | +104.4% | +61.0% | +42.9% | +4.8% | -69.9% | -62.6% | -67.0% | +14.4% | +381.0% |
Range$3.20M – $73.60M
CAGR+93.5%
Avg YoY Growth+133.3%
Median YoY Growth+101.4%
Current Streak2 quarters growth
Deferred Tax Assets and Other Non-Current Assets at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's deferred tax assets and other non-current assets?
- Neurocrine Biosciences (NBIX) reported deferred tax assets and other non-current assets of $73.60M in Q1 2026.
- How has Neurocrine Biosciences's deferred tax assets and other non-current assets changed year-over-year?
- Neurocrine Biosciences's deferred tax assets and other non-current assets increased by 381.0% year-over-year, from $15.30M to $73.60M.
- What is the long-term trend for Neurocrine Biosciences's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's deferred tax assets and other non-current assets has grown at a 56.2% compound annual growth rate (CAGR), from $6.40M to $59.50M.
- What does deferred tax assets and other non-current assets mean?
- The total value of long-term tax assets and other miscellaneous long-term assets.